首页> 美国卫生研究院文献>World Journal of Gastroenterology >Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis
【2h】

Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis

机译:肝癌患者经导管动脉栓塞治疗和发生肺转移的风险

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To investigate the relationship between transcatheter arterial embolization (TAE) and pulmonary metastasis in subjects with hepatocellular carcinoma (HCC).METHODS: A total of 287 patients with HCC followed up for more than 1 wk were included. 102 patients underwent transcatheter arterial embolization (TAE group) and 185 received conservative treatment (control group). The patients' chest X-rays and chest CT scans were examined for pulmonary metastasis.RESULTS: Patients with TAE had a median survival of 19.3 mo while that of the control group was only 10.0 mo (P < 0.05). Pulmonary metastasis occurred in 14 (13.7%) patients in the TAE group and 14 (7.6%) patients in the control group, there was no significant difference (P > 0.05). The 1-year, 2-year and 5-year cumulative incidence of pulmonary metastasis was 11.8%, 17.6% and 24.0% in the TAE group and 7.0%, 13.0% and 21.7% in the control group, respectively (P > 0.05). On the univariate analysis, tumor size, abnormal serum alanine aminotransferase levels and heterogeneity on sonography were significantly associated with pulmonary metastasis. However, on the multivariate analysis, only tumor size was significantly predictive of pulmonary metastasis.CONCLUSION: TAE is effective on prolonging survival of patients with HCC. It does not significantly increase the risk of pulmonary metastasis. Tumor size is the only significant predictive factor associated with lung metastasis.
机译:目的:探讨肝癌(HCC)患者经导管动脉栓塞(TAE)与肺转移之间的关系。方法:共纳入287例HCC患者,随访1周以上。 102例行经导管动脉栓塞术(TAE组),185例接受保守治疗(对照组)。结果:TAE患者的中位生存期为19.3 mo,而对照组的中位生存期仅为10.0 mo(P <0.05)。 TAE组有14例(13.7%)患者发生肺转移,对照组有14例(7.6%)发生肺转移,差异无统计学意义(P> 0.05)。 TAE组的1年,2年和5年的肺转移累积发生率分别为11.8%,17.6%和24.0%,对照组为7.0%,13.0%和21.7%(P> 0.05) 。单因素分析显示,肿瘤大小,血清丙氨酸氨基转移酶水平异常和超声检查的异质性与肺转移密切相关。然而,在多变量分析中,只有肿瘤的大小可以显着预测肺转移。结论:TAE对延长肝癌患者的生存有效。它不会显着增加肺转移的风险。肿瘤大小是与肺转移相关的唯一重要预测因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号